Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death, myocardial infarction, or stroke within 1 year, with no increased risk of bleeding.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 381; číslo 16; s. 1524 - 1534
Hlavní autoři:	Schüpke, Stefanie, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Bernlochner, Isabell, Wöhrle, Jochen, Richardt, Gert, Liebetrau, Christoph, Witzenbichler, Bernhard, Antoniucci, David, Akin, Ibrahim, Bott-Flügel, Lorenz, Fischer, Marcus, Landmesser, Ulf, Katus, Hugo A, Sibbing, Dirk, Seyfarth, Melchior, Janisch, Marion, Boncompagni, Duino, Hilz, Raphaela, Rottbauer, Wolfgang, Okrojek, Rainer, Möllmann, Helge, Hochholzer, Willibald, Migliorini, Angela, Cassese, Salvatore, Mollo, Pasquale, Xhepa, Erion, Kufner, Sebastian, Strehle, Axel, Leggewie, Stefan, Allali, Abdelhakim, Ndrepepa, Gjin, Schühlen, Helmut, Angiolillo, Dominick J, Hamm, Christian W, Hapfelmeier, Alexander, Tölg, Ralph, Trenk, Dietmar, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 17.10.2019
Témata:	Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - mortality Acute Coronary Syndrome - therapy Acute coronary syndromes Aged Bleeding Cerebral infarction Clinical trials Coronary Thrombosis - epidemiology Death Drug dosages Female Heart attacks Hemorrhage - chemically induced Humans Implants Incidence Kaplan-Meier Estimate Male Medical imaging Middle Aged Myocardial infarction Myocardial Infarction - epidemiology Myocardial Infarction - prevention & control Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride - adverse effects Prasugrel Hydrochloride - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Stents Stroke - epidemiology Stroke - prevention & control Thrombosis Ticagrelor - adverse effects Ticagrelor - therapeutic use Germany
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death, myocardial infarction, or stroke within 1 year, with no increased risk of bleeding.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1908973